Rodney Young - RAPT Therapeutics Principal CFO
| RAPT Stock | USD 1.20 0.05 4.35% |
Insider
Rodney Young is Principal CFO of RAPT Therapeutics
| Age | 62 |
| Address | 561 Eccles Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 489 9000 |
| Web | https://www.rapt.com |
Rodney Young Latest Insider Activity
Tracking and analyzing the buying and selling activities of Rodney Young against RAPT Therapeutics stock is an integral part of due diligence when investing in RAPT Therapeutics. Rodney Young insider activity provides valuable insight into whether RAPT Therapeutics is net buyers or sellers over its current business cycle. Note, RAPT Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell RAPT Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Rodney Young over six months ago Acquisition by Rodney Young of 90000 shares of RAPT Therapeutics at 24.75 subject to Rule 16b-3 |
RAPT Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4113) % which means that it has lost $0.4113 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7709) %, meaning that it created substantial loss on money invested by shareholders. RAPT Therapeutics' management efficiency ratios could be used to measure how well RAPT Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.57 in 2025. Return On Capital Employed is likely to drop to -0.74 in 2025. Total Current Liabilities is likely to gain to about 50.8 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 165.3 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Lynn Scherm | Tyra Biosciences | N/A | |
| Sanjay Chanda | AN2 Therapeutics | 60 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Piyush Patel | Tyra Biosciences | 59 | |
| Randi MD | Werewolf Therapeutics | 69 | |
| Hal MD | Pliant Therapeutics | N/A | |
| Craig Muir | Pliant Therapeutics | N/A | |
| Daniel Bensen | Tyra Biosciences | 49 | |
| Joan JD | Pharvaris BV | 60 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| MA MBA | Relay Therapeutics | 48 | |
| Melanie Morrison | Black Diamond Therapeutics | 50 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Stacey Davis | Xilio Development | N/A | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Hing Wong | HCW Biologics | 70 | |
| Evan Hecker | Ikena Oncology | N/A | |
| MBA BS | AN2 Therapeutics | 49 | |
| CPA CPA | Arvinas | 52 | |
Management Performance
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.41 |
RAPT Therapeutics Leadership Team
Elected by the shareholders, the RAPT Therapeutics' board of directors comprises two types of representatives: RAPT Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RAPT. The board's role is to monitor RAPT Therapeutics' management team and ensure that shareholders' interests are well served. RAPT Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RAPT Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gwen Carscadden, Chief Officer | ||
| Rodney Young, Principal CFO | ||
| David Wustrow, Senior Development | ||
| William Ho, Chief Officer | ||
| Jennifer Nicholson, Senior Assurance | ||
| Michael Listgarten, General Counsel | ||
| William MD, Chief Officer | ||
| Steve Young, Vice Technology | ||
| Paul Kassner, Senior Biology | ||
| Nipun MBA, Senior Operations | ||
| Brian MD, President CEO | ||
| Dirk Brockstedt, Chief Officer |
RAPT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RAPT Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | (74.76 M) | ||||
| Shares Outstanding | 132.01 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 96.42 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Book | 0.80 X | ||||
| Price To Sales | 411.22 X | ||||
| Gross Profit | 1.53 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.